Dupont Capital Management Corp Takes $274,000 Position in Stryker Corporation (SYK)

Dupont Capital Management Corp bought a new position in Stryker Corporation (NYSE:SYK) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 1,927 shares of the medical technology company’s stock, valued at approximately $274,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Andra AP fonden grew its stake in shares of Stryker Corporation by 3.1% during the 3rd quarter. Andra AP fonden now owns 173,100 shares of the medical technology company’s stock valued at $24,584,000 after buying an additional 5,200 shares during the period. Parthenon LLC grew its stake in shares of Stryker Corporation by 2.5% during the 3rd quarter. Parthenon LLC now owns 44,120 shares of the medical technology company’s stock valued at $6,266,000 after buying an additional 1,060 shares during the period. BP PLC grew its stake in shares of Stryker Corporation by 12.9% during the 3rd quarter. BP PLC now owns 39,500 shares of the medical technology company’s stock valued at $5,610,000 after buying an additional 4,500 shares during the period. Ramsay Stattman Vela & Price Inc. grew its stake in shares of Stryker Corporation by 0.7% during the 3rd quarter. Ramsay Stattman Vela & Price Inc. now owns 47,418 shares of the medical technology company’s stock valued at $6,734,000 after buying an additional 315 shares during the period. Finally, Brightworth grew its stake in shares of Stryker Corporation by 2,755.7% during the 3rd quarter. Brightworth now owns 41,751 shares of the medical technology company’s stock valued at $5,930,000 after buying an additional 40,289 shares during the period. 74.15% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.40% of the stock is currently owned by insiders.

Several brokerages have recently issued reports on SYK. SunTrust Banks, Inc. reissued a “buy” rating and set a $161.00 price objective on shares of Stryker Corporation in a research note on Monday, October 2nd. Stifel Nicolaus boosted their price objective on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Oppenheimer Holdings, Inc. set a $156.00 price objective on shares of Stryker Corporation and gave the company a “hold” rating in a research note on Monday, October 30th. Canaccord Genuity boosted their price objective on shares of Stryker Corporation from $155.00 to $162.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Finally, BidaskClub cut shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the company’s stock. Stryker Corporation has an average rating of “Hold” and a consensus target price of $151.52.

Stryker Corporation (NYSE SYK) opened at $155.75 on Tuesday. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $160.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. The company has a market cap of $57,812.22, a price-to-earnings ratio of 24.48, a price-to-earnings-growth ratio of 2.43 and a beta of 0.79.

Stryker Corporation (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.02. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The firm’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.39 EPS. equities analysts expect that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Dupont Capital Management Corp Takes $274,000 Position in Stryker Corporation (SYK)” was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/14/dupont-capital-management-corp-takes-274000-position-in-stryker-corporation-syk.html.

Stryker Corporation Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply